Page last updated: 2024-12-05

maleic anhydride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Maleic anhydride is a white crystalline organic compound, also known as toxilic anhydride. It is produced industrially by the catalytic oxidation of benzene or n-butane. It is a valuable starting material for the production of various industrial chemicals, including unsaturated polyester resins, alkyd resins, and agricultural chemicals. Maleic anhydride is used as a monomer in the production of polymers, as a cross-linking agent in resins, and as a drying agent in paints and varnishes. It is also used in the manufacture of pharmaceuticals, pesticides, and other chemicals. Maleic anhydride is a highly reactive compound and is considered a potential human carcinogen. It is important to handle it with care and use appropriate safety precautions.'

Maleic Anhydrides: Used in copolymerization reactions, in the Diels-Alder(diene)synthesis, in the preparation of resins, pharmaceuticals and agricultural chemicals. It is a powerful irritant and causes burns. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

maleic anhydride : A cyclic dicarboxylic anhydride that is the cyclic anhydride of maleic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7923
CHEMBL ID374159
CHEBI ID474859
MeSH IDM0012925

Synonyms (95)

Synonym
anhydride, maleic
toxilic anhydride
nsc-137651
dihydro-2,5-dioxofuran
cis-butenedioic anhydride
maleic anhydride
nsc-137652
nsc137653
nsc137651
nsc-137653
maleic acid anhydride
108-31-6
2,5-furandione
nsc137652
maleic anhydride treated bsa
nsc-9568
nsc9568
2,5-dihydrofuran-2,5-dione
bdbm7812
inchi=1/c4h2o3/c5-3-1-2-4(6)7-3/h1-2
furan-2,5-dione
ccris 2941
rcra waste number u147
hsdb 183
einecs 203-571-6
anhydrid kyseliny maleinove [czech]
brn 0106909
maleinanhydrid [czech]
nsc 137651
rcra waste no. u147
ai3-24283
un2215
maleic anhydride, powder, 95%
maleic anhydride, 99%
CHEMBL374159
maleic anhydrides
FT-0693473
M0005
chebi:474859 ,
AKOS000121041
A801842
NCGC00248595-01
furan-2,5-quinone
ec 203-571-6
maleinanhydrid
maleic anhydride [un2215] [corrosive]
anhydrid kyseliny maleinove
5-17-11-00055 (beilstein handbook reference)
v5877zjz25 ,
unii-v5877zjz25
24937-72-2
dtxcid804166
tox21_200406
cas-108-31-6
NCGC00257960-01
dtxsid7024166 ,
FT-0670909
BP-20394
FT-0628122
EPITOPE ID:122673
maleic anhydride [mi]
maleic anhydride [hsdb]
maleic anhydride [inci]
AKOS025243943
c4h2o3
maleicanhydride
fumaric anhydride
2,5-furanedione
lytron 820 (salt/mix)
maleic anhydride, briquettes
un 2215
m 188
lytron 810 (salt/mix)
mfcd00005518
J-002092
J-521668
F0001-0164
maleic anhydride, saj first grade, >=98.0%
maleic anhydride, puriss., >=99.0% (nt)
maleic anhydride, 95% (may contain up to 5% maleic acid)
maleic anhydride, for synthesis, 99.0%
CS-Z0016
maleic anhydride (briquette)
maleic anhydride (2,3-13c2)
Q412377
(z)-butanedioic acid anhydride
184288-31-1
STL197476
EN300-17997
maleic anhydride-13c4
2,5-furandion
bm 10
2,5-dioxo-dihydrofuran
crystal man
nourymix ma 901

Research Excerpts

Overview

Maleic anhydride is an electron-acceptor monomer. Property comes from reactive double bonds and also reactive anHydride groups.

ExcerptReferenceRelevance
"Maleic anhydride is an electron-acceptor monomer where the property comes from reactive double bonds and also reactive anhydride groups."( A review on various maleic anhydride antimicrobial polymers.
Jalageri, MD; Nagaraja, A; Puttaiahgowda, YM; Raghava Reddy, K; Raghu, AV, 2019
)
1.56

Effects

ExcerptReferenceRelevance
"Maleic anhydride has many uses in industry, but workers' exposure to it is poorly known. "( Determination of maleic anhydride in occupational atmospheres.
Hämeilä, M; Kuusimäki, L; Pfäffli, P; Wirmoila, R, 2002
)
2.1

Toxicity

ExcerptReferenceRelevance
" Hence, it is concluded that the polymer SMA injected at above doses appears to be safe in our experiment."( Preclinical toxicity study of a male injectable antifertility agent (styrene maleic anhydride) in rhesus monkeys, Macaca mulatta.
Nath, D; Sethi, N; Singh, RK; Srivastava, RK, 1991
)
0.51
" Hence, the polymer is safe at the doses used within 6 months of injection."( Long-term toxicity studies of styrene maleic anhydride in rats.
Nath, D; Sethi, N; Singh, RK; Srivastava, RK, 1990
)
0.55
" The results suggest the polymer SMA to be safe up to 5 times CD in monkeys."( Chronic toxicity of styrene maleic anhydride, a male contraceptive, in rhesus monkeys (Macaca mulatta).
Bhatia, GS; Sethi, N; Singh, RK; Sinha, N; Srivastava, RK, 1990
)
0.57
"The toxic effect and antitumor activity of neocarzinostatin (NCS) and SMANCS [copoly(styrenemaleic acid)-conjugated NCS] were greatly affected by N-(2-mercaptopropionyl)-glycine [tiopronin] both in vitro and in vivo, in cultured HeLa cells and RL male 1 tumor-bearing mice."( Differential neutralizing effect of tiopronin on the toxicity of neocarzinostatin and SMANCS: a new rescue cancer chemotherapy.
Maeda, H; Miki, T; Oda, T; Yamamoto, H, 1989
)
0.28
" Such PEGylated complexes with the ability to deshield the PEG layer at the target tissues hold great promise for efficient and safe gene delivery in vivo."( Tumor Acidity-Induced Sheddable Polyethylenimine-Poly(trimethylene carbonate)/DNA/Polyethylene Glycol-2,3-Dimethylmaleicanhydride Ternary Complex for Efficient and Safe Gene Delivery.
Deng, X; Lu, J; Shao, L; Wu, Y; Zhao, C, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"The clinical effect and safety of Lp-TAE alone and combined with radiofrequency (RF) capacitive hyperthermia (HT) were evaluated in 20 patients with hepatocellular carcinoma (HCC) associated with cirrhosis of the liver."( Trans-catheter hepatic arterial injection of lipiodol soluble anti-cancer agent SMANCS and ADR suspension in lipiodol combined with arterial embolization and local hyperthermia for treatment of hepatocellular carcinoma.
Hara, K; Inatsuki, S; Jinno, K; Kobashi, H; Moriwaki, S; Okamoto, T; Toki, H; Tokuyama, K; Wada, T; Yumoto, Y,
)
0.13
"0 cm) in main tumor diameter were treated by SMANCS-TAE (20 cases) or SMANCS-TAI (4 cases) combined with PEI."( [SMANCS-TAE combined with PEI in the treatment for hepatocellular carcinoma].
Arata, S; Fujii, T; Hori, A; Isozaki, T; Kiba, T; Kitamura, T; Kondo, M; Morimoto, M; Morita, K; Numata, K; Okazaki, H; Saito, S; Sekihara, H; Shimamura, T; Shirato, K; Tanaka, K, 1998
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The main findings of the Bayesian study are consistent with our chemistry-based approach and our previously published assessment of the key determinants of sensitization potency, in particular the relatively high predictive value found for chemical reactivity data and the relatively low predictive value for bioavailability parameters."( Integrated testing and assessment approaches for skin sensitization: a commentary.
Patlewicz, GY; Roberts, DW, 2014
)
0.4
" It is concluded that the letrozole delivery system appears to overcome the limitations associated with letrozole by providing enhanced drug dissolution rate, controlled release and improved bioavailability of the incorporated drug and, therefore, seems to have extended therapeutic effects."( Letrozole dispersed on poly (vinyl alcohol) anchored maleic anhydride grafted low density polyethylene: a controlled drug delivery system for treatment of breast cancer.
Adhikari, B; Chaudhury, K; Siddiqa, AJ, 2014
)
0.65
" Thus, our modified drug delivery nanocomposites afforded higher drug bioavailability with large potential for fabrication as long-acting drug delivery nanocomposites, especially with hydrophobic drugs inducing the growth of osteoblastic bone cells."( Fabrication of bioactive rifampicin loaded κ-Car-MA-INH/Nano hydroxyapatite composite for tuberculosis osteomyelitis infected tissue regeneration.
Amarnath Praphakar, R; Rajan, M; Sam Ebenezer, R; Shakila, H; Sumathra, M; Vignesh, S, 2019
)
0.51
"The poor water solubility and inadequate oral bioavailability of gefitinib (Gef) remain a critical issue to achieve the therapeutic outcomes."( Poly(maleic anhydride-alt-1-octadecene)-based bioadhesive nanovehicles improve oral bioavailability of poor water-soluble gefitinib.
Li, J; Li, Y; Qian, X; Shan, Y; Wang, G; Xie, Y; Zhang, M; Zhang, X; Zhang, Z, 2022
)
1.24

Dosage Studied

ExcerptRelevanceReference
" Metastatic lung cancer was declining in the initial dosage and 23 months later disappeared after the third dosage."( [A case of massive hepatoma which responded to SMANCS/Lipiodol regimen with intra-arterial infusion].
Fuchigami, T; Konno, T; Kubo, M; Maeda, H; Murata, S, 1989
)
0.28
" The advantages of this therapy include: (1) selective deposition of Lipiodol with the anti-cancer drug in the target tumor, (2) a pronounced and long-lasting anti-cancer effect, (3) enhanced visualization of the tumor on x-ray examinations for a prolonged period which also facilitated the long-term follow-up, (4) semiquantitative evaluation of the dosage regimen by x-ray examination before further administration, (5) general applicability due to procedural simplicity, and (6) little side effect."( Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium.
Iwai, K; Konno, T; Maeda, H; Maki, S; Miyauchi, Y; Tashiro, S; Uchida, M, 1984
)
0.27
" Differential diagnosis of primary or metastatic cancer became possible and dosing regimen can be determined since a presence of the contrast medium is restricted to the tumor area and it parallels to that of the drug being dissolved."( [Tumor selective drug delivery with lipid contrast medium (smancs/lipiodol): sustained antitumor effect, enhanced diagnostic value and quantification of dosage regimen].
Iwai, K; Konno, T; Maeda, H; Maki, S; Tashiro, S, 1984
)
0.27
", CT-scan), and thus the optimal dosing regimen can be determined and offers a diagnostic advantage."( [SMANCS/lipiodol].
Maeda, H, 1994
)
0.29
" First arterial administration of SMANCS was performed on May in 1994, followed by 6 successive procedures with an interval of about 2 months (total dosage 36 mg), resulting in remarkable tumor shrinkage and tumor marker normalization."( [A case of giant hepatocellular carcinoma successfully treated by arterial administration of SMANCS].
Ishii, K; Kinoshita, T; Miyasato, S; Miyazaki, A; Ohira, S; Sakurada, H; Shibuya, D; Tomiya, Y; Yajima, Y, 1996
)
0.29
" Thus, an increase of infusion dosage or repeated infusions were recommended for such cases."( [Arterial infusion chemotherapy with SMANCS-Lipiodol for multiple hepatocellular carcinoma].
Doai, K; Hasebe, S; Honda, M; Kuniyasu, Y; Matsuoka, S; Obuchi, M; Satoh, S; Shima, H; Takizawa, K; Uchiyama, K, 1998
)
0.3
" The stability (shelf life) of the prepared nanostructured dosage forms was evaluated."( A new biocompatible nanoparticle delivery system for the release of fibrinolytic drugs.
Bartoli, C; Chiellini, E; Chiellini, F; Farina, C; Fiorentino, B; Fiumi, C; Piras, AM, 2008
)
0.35
"75 were accessible in a completely homogeneous system by changing reaction temperature, reaction time, the dosage of catalyst, and the molar ratio of maleic anhydride to anhydroxylose unit in XH."( Homogeneous esterification of xylan-rich hemicelluloses with maleic anhydride in ionic liquid.
Peng, XW; Ren, JL; Sun, RC, 2010
)
0.8
"8:1, MA:β-CD = 6:1, reaction temperature of 80 °C, reaction time of 6 h, and dropping time of 40 min when MA was dosed as a substrate, and SSS and KPS were dosed as dropping reactants simultaneously."( Research on the synthesis and scale inhibition performance of a new terpolymer scale inhibitor.
Bao, Y; Li, M; Zhang, Y, 2016
)
0.43
" First, hollow cGEL tubes were fabricated by a continuous dosing and templating process."( Dual-Component Gelatinous Peptide/Reactive Oligomer Formulations as Conduit Material and Luminal Filler for Peripheral Nerve Regeneration.
Bhatnagar, D; Franz, S; Hacker, MC; Kaplan, HM; Kohn, J; Kohn-Polster, C; Richtmyer, M; Schulz-Siegmund, M; Springwald, AH; Starke, A; Woloszyn, DJ, 2017
)
0.46
" Formulation with high polymer dosage showed better tumor targeting and antitumor activity, and activity of inhibiting HepG2 with higher content of SA-containing glycosphingolipids was higher than that of anti-B16."( Phenylboronic acid-modified polymaleic anhydride-F127 micelles for pH-activated targeting delivery of doxorubicin.
Chen, S; Feng, R; Li, H; Song, Z; Teng, F; Wang, M; Zhu, L, 2022
)
1
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclic dicarboxylic anhydrideAn acid anhydride derived by loss of water between two carboxylic groups in the same molecule so as to close a ring.
furansCompounds containing at least one furan ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.28320.006038.004119,952.5996AID1159521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[tau protein] kinase Oryctolagus cuniculus (rabbit)IC50 (µMol)100.00000.00201.69306.0000AID1796098
Glycogen synthase kinase-3 alphaHomo sapiens (human)IC50 (µMol)100.00000.00101.22499.1000AID282721
Glycogen synthase kinase-3 betaHomo sapiens (human)IC50 (µMol)100.00000.00060.801310.0000AID282721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (97)

Processvia Protein(s)Taxonomy
regulation of systemic arterial blood pressureGlycogen synthase kinase-3 alphaHomo sapiens (human)
cardiac left ventricle morphogenesisGlycogen synthase kinase-3 alphaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
nervous system developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of UDP-glucose catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell migrationGlycogen synthase kinase-3 alphaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to insulin stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 alphaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of heart contractionGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glucose importGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of insulin receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to lithium ionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cellular response to glucocorticoid stimulusGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating adrenergic receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
autosome genomic imprintingGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of mitophagyGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of amyloid-beta formationGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of protein targeting to mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen synthase activity, transferring glucose-1-phosphateGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 alphaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 alphaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
ER overload responseGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of apoptotic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
epithelial to mesenchymal transitionGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell-matrix adhesionGlycogen synthase kinase-3 betaHomo sapiens (human)
glycogen metabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrion organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
dopamine receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of autophagyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of gene expressionGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-serine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
peptidyl-threonine phosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
viral protein processingGlycogen synthase kinase-3 betaHomo sapiens (human)
hippocampus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
establishment of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
maintenance of cell polarityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of cell migrationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axon extensionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein-containing complex assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein ubiquitinationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of phosphoprotein phosphatase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule-based processGlycogen synthase kinase-3 betaHomo sapiens (human)
intracellular signal transductionGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to interleukin-3Glycogen synthase kinase-3 betaHomo sapiens (human)
regulation of circadian rhythmGlycogen synthase kinase-3 betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of GTPase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of osteoblast differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen biosynthetic processGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of cilium assemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein catabolic processGlycogen synthase kinase-3 betaHomo sapiens (human)
protein autophosphorylationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of protein export from nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of dendrite morphogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of axonogenesisGlycogen synthase kinase-3 betaHomo sapiens (human)
canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
excitatory postsynaptic potentialGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule cytoskeleton organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of calcineurin-NFAT signaling cascadeGlycogen synthase kinase-3 betaHomo sapiens (human)
superior temporal gyrus developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to retinoic acidGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of canonical Wnt signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandGlycogen synthase kinase-3 betaHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionGlycogen synthase kinase-3 betaHomo sapiens (human)
neuron projection organizationGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of microtubule anchoring at centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of cellular response to heatGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein localization to nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of long-term synaptic potentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of protein acetylationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to ciliumGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of dopaminergic neuron differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
cellular response to amyloid-betaGlycogen synthase kinase-3 betaHomo sapiens (human)
positive regulation of protein localization to centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complex disassemblyGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of type B pancreatic cell developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of glycogen (starch) synthase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of mesenchymal stem cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
negative regulation of TOR signalingGlycogen synthase kinase-3 betaHomo sapiens (human)
regulation of neuron projection developmentGlycogen synthase kinase-3 betaHomo sapiens (human)
cell differentiationGlycogen synthase kinase-3 betaHomo sapiens (human)
insulin receptor signaling pathwayGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
protein serine/threonine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
signaling receptor bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 alphaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 alphaHomo sapiens (human)
protease bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
p53 bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine/threonine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ATP bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
ubiquitin protein ligase bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein kinase A catalytic subunit bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
dynactin bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau protein bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
tau-protein kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
NF-kappaB bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingGlycogen synthase kinase-3 betaHomo sapiens (human)
protein serine kinase activityGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
mitochondrionGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 alphaHomo sapiens (human)
neuronal cell bodyGlycogen synthase kinase-3 alphaHomo sapiens (human)
apical dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 alphaHomo sapiens (human)
proximal dendriteGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 alphaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 alphaHomo sapiens (human)
axonGlycogen synthase kinase-3 alphaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 alphaHomo sapiens (human)
glutamatergic synapseGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
mitochondrionGlycogen synthase kinase-3 betaHomo sapiens (human)
centrosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
plasma membraneGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
dendriteGlycogen synthase kinase-3 betaHomo sapiens (human)
beta-catenin destruction complexGlycogen synthase kinase-3 betaHomo sapiens (human)
presynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
postsynapseGlycogen synthase kinase-3 betaHomo sapiens (human)
Wnt signalosomeGlycogen synthase kinase-3 betaHomo sapiens (human)
cytosolGlycogen synthase kinase-3 betaHomo sapiens (human)
axonGlycogen synthase kinase-3 betaHomo sapiens (human)
nucleusGlycogen synthase kinase-3 betaHomo sapiens (human)
cytoplasmGlycogen synthase kinase-3 betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1203999Antiinflammatory activity against mouse MB49-I cells assessed as inhibition of IFN-gamma/TNFalpha-NO production pretreated at 50 uM after 24 hrs by Griess reaction relative to vehicle treated control2015European journal of medicinal chemistry, , Volume: 96Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
AID282721Inhibition of rabbit GSK32005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
AID1203998Antiinflammatory activity against mouse MB49-I cells assessed as inhibition of IFN-gamma/TNFalpha-NO production pretreated at 10 uM after 24 hrs by Griess reaction relative to vehicle treated control2015European journal of medicinal chemistry, , Volume: 96Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells.
AID1796098Kinase Inhibition Assay from Article 10.1021/jm040895g: \\SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.\\2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (766)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990164 (21.41)18.7374
1990's143 (18.67)18.2507
2000's146 (19.06)29.6817
2010's240 (31.33)24.3611
2020's73 (9.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 74.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index74.14 (24.57)
Research Supply Index6.70 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index131.43 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (74.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (2.00%)5.53%
Reviews26 (3.25%)6.00%
Case Studies43 (5.38%)4.05%
Observational0 (0.00%)0.25%
Other714 (89.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]